A detailed history of China Universal Asset Management Co., Ltd. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 15,409 shares of CRSP stock, worth $830,545. This represents 0.14% of its overall portfolio holdings.

Number of Shares
15,409
Previous 15,409 -0.0%
Holding current value
$830,545
Previous $1.05 Million -0.0%
% of portfolio
0.14%
Previous 0.13%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$60.67 - $89.12 $377,124 - $553,969
6,216 Added 67.62%
15,409 $1.05 Million
Q4 2023

May 21, 2024

SELL
$38.62 - $72.18 $240,061 - $448,670
-6,216 Reduced 40.34%
9,193 $575,000
Q4 2023

Jan 23, 2024

BUY
$38.62 - $72.18 $276,210 - $516,231
7,152 Added 350.42%
9,193 $575,000
Q3 2023

May 21, 2024

BUY
$45.39 - $59.0 $45,707 - $59,413
1,007 Added 97.39%
2,041 $92,000
Q3 2023

Oct 30, 2023

BUY
$45.39 - $59.0 $45,707 - $59,413
1,007 Added 97.39%
2,041 $93,000
Q2 2023

May 21, 2024

SELL
$43.47 - $67.77 $1,347 - $2,100
-31 Reduced 2.91%
1,034 $58,000
Q2 2023

Jul 27, 2023

SELL
$43.47 - $67.77 $1,347 - $2,100
-31 Reduced 2.91%
1,034 $58,000
Q1 2023

May 21, 2024

SELL
$41.0 - $56.12 $103,853 - $142,151
-2,533 Reduced 70.4%
1,065 $48,000
Q1 2023

Apr 27, 2023

SELL
$41.0 - $56.12 $103,853 - $142,151
-2,533 Reduced 70.4%
1,065 $48,000
Q4 2022

May 21, 2024

SELL
$39.19 - $65.67 $462,873 - $775,628
-11,811 Reduced 76.65%
3,598 $146,000
Q4 2022

Jan 31, 2023

SELL
$39.19 - $65.67 $822,402 - $1.38 Million
-20,985 Reduced 85.36%
3,598 $146,000
Q3 2022

Oct 21, 2022

BUY
$61.1 - $83.78 $1.42 Million - $1.95 Million
23,250 Added 1744.19%
24,583 $1.61 Million
Q1 2022

Apr 25, 2022

BUY
$53.19 - $79.24 $70,902 - $105,626
1,333 New
1,333 $84,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.2B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.